|
Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer and infectious diseases, announces it has been granted European patents EP3768305 and EP3768830, issued by the European Patent Office (EPO) on 7 February 2023. The patents cover the pharmaceutical composition and method of use for the treatment of cancer for ValoTx’s lead product PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus-1). These two patents cover its lead virus VALO-D102 and the peptides coating the virus, MAGE-A3 and NY-ESO-1.
PeptiCRAd-1 is a first-in-class cancer immunotherapy drug candidate that is designed to stimulate systemic tumour-directed cytotoxic T-cell responses in cancer patients. Combined with its local immune modulation effect at the tumour site, it has the potential to deliver synergistic clinical outcomes in combination with immune checkpoint inhibitors. A Phase 1 trial is now open for enrollment for PeptiCRAd-1 in combination with pembrolizumab in melanoma, triple-negative breast cancer and non-small cell lung cancer.
Dr. Sari Pesonen, CSO at Valo Tx, commented, “Securing these important patents underscores our innovative oncolytic adenovirus approach, which enhances tumour-specific T-cell responses in cancer patients using an oncolytic virus combined with target peptides. These granted patents will allow us to further capitalize upon our powerful platform that uses VALO-D102 virus as a backbone for novel PeptiCRAds using alternative peptides.”
Valo Therapeutics Oy (Helsinki) is an immunotherapy company that is developing antigen-coated oncolytic viruses and vaccine vectors as therapeutic vaccines against cancer and infectious disease.
|